迪巧品牌怎么样 申请店铺

我要投票 迪巧在钙片行业中的票数:956 更新时间:2025-12-13
迪巧是哪个国家的品牌?「迪巧」是安士制药(中山)有限公司旗下著名品牌。该品牌发源于广东,由创始人徐清波在2003-09-19期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力迪巧品牌出海!将品牌入驻外推网,定制迪巧品牌推广信息,可以显著提高迪巧产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

迪巧怎么样

迪巧是由美国安士制药有限公司按F.LA标准在美国生产的品牌产品。精选全球50多个优质钙源,是经过国际先进工艺提纯的精制碳酸钙,安全性极高。迪巧科学添加了维生素D3,具有安全、足量、好吸收的三大优点。同时,迪巧针对中国不同年龄段人群对钙制剂需求的特点,特别设计了个性配方和口味。有专为0-3岁宝宝设计的迪巧小儿碳酸钙D3颗粒,专为3岁以上儿童设计的迪巧儿童维D钙咀嚼片,专为成人计的迪巧维D钙咀嚼片以及专为更年期女性设计的迪巧秀源女性片。

迪巧是中国优生科学协会唯一推荐钙补充剂,经中国优生科学协会审核论证,连续10年被作为唯一推荐补钙制剂。2010年中国家庭药箱调查显示,迪巧名列中国居民信赖的家庭常备药排名前三。该调查由中国非处方药物协会、中国医药质量管理协会、中国药学会发布。迪巧荣获中国健康年度总评榜“最受欢迎补钙用药”。2010年39健康网开展了健康年度总评榜,由网民自行投票选出最欢迎的药品品牌,迪巧荣获最受欢迎补钙用药之一。迪巧连续3年荣获“健康中国2010中国药品品牌榜”上榜品牌称号。迪巧连续3年荣获“2008-2009年度店员推荐率最高品牌”。2009年10月29日至31日,《中国药店》杂志社举办了第九届中国药店高峰论坛暨"2008-2009年度店员推荐率最高品牌"揭晓会议,来自全国连锁店、及卫生部、国家药监局的百余人到场。迪巧深受药店专业人员信赖,被大会评为“2008-2009年度店员推荐率最高品牌”。这已经是迪巧连续三年荣获此奖项。

安士制药(中山)有限公司位于广东省中山市火炬开发区国家健康基地,是由以美国安士集团有限公司,中山市健康科技产业基地发展有限公司和百洋集团有限公司为主的几家公司共同投资的一家集科研开发、生产和市场建设于一体的新型医药生产企业。

公司首期占地面积二万多平方米,拥有近一万四千平方米的现代化厂房,已建成两个固体制剂车间、冻干粉针车间、软胶囊车间和质检中心。全部生产车间都通过了国家和省食品药品监督管理局认证中心的GMP认证。固体制剂车间于2010年5月通过美国FDA现场验证。

安士以科研开发为先导,研究开发自产产品。同时引进国外先进生产技术及产品信息,已形成的迪巧系列补钙制剂为国内名列前茅的大品种。此外,安士一直致力于处方药出口美国为主攻目标,培育一支适应国际化生产要求的管理团队和员工队伍。

2007年3月,安士生物科技(中山)有限公司成立,专门从事保健品的软胶囊研发和生产,从而满足软胶囊制剂在国内外市场销售快速发展的需要。

安士制药(中山)有限公司的宗旨是进一步提高安士品牌的美誉度和信任度,极大地丰富安士与人类健康息息相关的品牌内涵。公司的目标是建立一个适应新剂型、新品种发展的药品生产基地,努力在制药市场上形成一个重要的、诚信可靠的企业,为人类的健康事业做出贡献。

Diqiao is a brand product manufactured in the United States by axis Pharmaceutical Co., Ltd. according to f.la standard. More than 50 high-quality calcium sources in the world are selected. They are refined calcium carbonate purified by international advanced technology, with high safety. Diqiao added vitamin D3 scientifically, which has three advantages of safety, sufficient quantity and good absorption. At the same time, Diqiao specially designed the individual formula and taste according to the characteristics of different age groups in China. There are Diqiao children's calcium carbonate D3 granules specially designed for 0-3 years old children, Diqiao children's vitamin D calcium chewable tablets specially designed for children over 3 years old, Diqiao vitamin D calcium chewable tablets specially designed for adults and Diqiao Xiuyuan women's tablets specially designed for menopausal women. Diqiao is the only calcium supplement recommended by China eugenics Association. It has been the only calcium supplement recommended by China eugenics Association for 10 consecutive years. According to the 2010 survey of family medicine kits in China, Diqiao ranked in the top three list of household medicines trusted by Chinese residents. The survey was released by China over the counter drug association, China Pharmaceutical Quality Management Association and China Pharmaceutical Association. Diqiao won the "most popular calcium supplement" in China's annual health review. In 2010, 39 health.com launched the annual health evaluation list, and the Internet users voted to select the most popular drug brand. Diqiao won one of the most popular calcium supplements. Diqiao has won the title of "healthy China 2010 Chinese drug brand list" for three consecutive years. Diqiao has been awarded "the highest brand recommended by shop assistants in 2008-2009" for three consecutive years. From October 29 to 31, 2009, China drugstore magazine Co., Ltd. held the 9th China drugstore Summit Forum and the unveiling meeting of "the highest recommended brand of staff in 2008-2009". More than 100 people from the national chain stores, the Ministry of health and the State Food and Drug Administration attended. Diqiao is deeply trusted by drugstore professionals and was rated as the "top brand with the highest recommended rate of salesmen in 2008-2009" by the conference. This is the third consecutive year that Diqiao has won this award. Anshi Pharmaceutical (Zhongshan) Co., Ltd. is located in the national health base of Torch Development Zone, Zhongshan City, Guangdong Province. It is a new pharmaceutical production enterprise, which is jointly invested by several companies mainly including Anshi Group Co., Ltd., Zhongshan Health Science and Technology Industrial Base Development Co., Ltd. and Baiyang Group Co., Ltd. The first phase of the company covers an area of more than 20000 square meters, with a modern plant of nearly 14000 square meters. Two solid preparation workshops, freeze-dried powder injection workshops, soft capsule workshops and quality inspection centers have been built. All production workshops have passed the GMP certification of national and provincial food and Drug Administration certification center. The solid preparation workshop passed the FDA field verification in May 2010. With scientific research and development as the guide, axis researches and develops its own products. At the same time, the introduction of foreign advanced production technology and product information, has formed Diqiao series of calcium supplements for the domestic top big varieties. In addition, axis has been committed to the export of prescription drugs to the United States as the main goal, and cultivate a management team and staff team to meet the requirements of international production. In March 2007, axis Biotechnology (Zhongshan) Co., Ltd. was established, specializing in the research, development and production of soft capsules for health products, so as to meet the needs of rapid development of soft capsule sales in domestic and foreign markets. The aim of axis Pharmaceutical (Zhongshan) Co., Ltd. is to further improve the reputation and trust of axis brand and greatly enrich the brand connotation of axis closely related to human health. The company's goal is to establish a pharmaceutical production base to adapt to the development of new dosage forms and new varieties, strive to form an important, honest and reliable enterprise in the pharmaceutical market, and make contributions to human health.

本文链接: https://brand.waitui.com/7cdc17c05.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

应对老年护理刚需,四部门发布《老年护理服务能力提升行动方案》

近日,国家卫生健康委、国家医保局、国家中医药局和国家疾控局四部门发布《老年护理服务能力提升行动方案》(以下简称《行动方案》)提出,到2027年,老年护理资源有效扩容,覆盖机构、社区、居家的老年护理服务体系逐步完善,从业人员服务能力不断提升,老年护理服务持续改善,服务连续性、可及性、规范性持续提高,老年人获得感不断增强。提升老年护理服务能力是深入贯彻实施积极应对人口老龄化国家战略的具体举措。截至2024年底,我国60岁及以上人口数达3.1亿,占总人口的22%,老年人特别是失能老年人对医疗护理服务呈现迫切的刚性需求。(央视新闻)

2小时前

消息人士称英伟达考虑提高H200芯片产量

消息人士称,英伟达考虑提高H200芯片产量。(新浪财经)

2小时前

中国造高端工业母机在沈阳下线交付

记者13日从通用技术沈阳机床获悉,由通用技术集团与东方电气集团联合研发的4台高端五轴联动数控机床12日在沈阳下线交付。这一合作在取得重大技术突破的同时,还打破了“研用脱节”的产业困境,开创了国产工业母机研制的新模式。长期以来,国产高端数控机床面临“研发投入大、周期长、验证难”的系统性瓶颈——企业闭门研发与市场实际需求脱节,产品因缺乏真实工况下的长期验证,陷入“用户不愿用、不敢用,技术难迭代、难成熟”的恶性循环,严重制约产业高质量发展。(中新网)

2小时前

金融时报:将坚持内需主导放在首位

金融时报评论员发布文章称,12月10日至11日,中央经济工作会议在京举行。会议聚焦“当前怎么看”和“明年怎么干”,为中国经济高质量发展把舵定向。站在“十四五”规划收官与“十五五”规划谋篇的历史交汇点,会议强调持续扩大内需、优化供给,将“坚持内需主导,建设强大国内市场”确定为明年经济工作重点任务之首。未来一个时期,我国国内市场主导国民经济循环的特征将更为明显。在内外部发展环境更趋严峻复杂的大背景下,只有坚持立足国内,全方位扩大内需、建设强大国内市场,增强发展主动性,才能够在国际风云变幻中,牢牢把握发展主动权。着眼明年经济社会发展目标任务,做强国内大循环,建设强大国内市场,以国内循环的稳定性对冲国际循环的不确定性,必须坚持内需的主导地位。坚持内需主导,全方位扩大国内需求,要大力提振居民消费。坚持内需主导,全方位扩大国内需求,要推动投资止跌回稳。将坚持内需主导放在首位,是党和国家对当前经济形势的深刻洞察。要全面贯彻明年经济工作的总体要求和政策取向,加快培育完整内需体系,形成消费和投资相互促进的良性循环,将超大规模市场的潜力转化为现实增长动力。

2小时前

脑虎科技:公司“三全”脑机接口产品成功完成首例临床试验

在今日举行的2025天桥脑科学研究院脑机接口与人工智能论坛中,脑虎科技方面表示,公司自主研发的国内首款、国际第二款内置电池的全植入、全无线、全功能(“三全”)脑机接口产品,在复旦大学附属华山医院毛颖、陈亮教授团队的主持下,成功完成首例临床试验。(财联社)

2小时前

本页详细列出关于迪巧的品牌信息,含品牌所属公司介绍,迪巧所处行业的品牌地位及优势。
咨询